In an exploratory analysis of a predefined subgroup of @ patients with poor prognosis disease , @ ( @ % ) died ( @ in the standard chemotherapy group and @ in the bevacizumab group ) , and a significant difference in overall survival was noted between women who received bevacizumab plus chemotherapy and those who received chemotherapy alone ( restricted mean survival time @ months -LSB- @ % CI @-@ -RSB- with standard chemotherapy vs @ months -LSB- @-@ -RSB- with bevacizumab ; log-rank p = @ ) .